Piper Sandler analyst Matt O’Brien notes that five Medicare Administrative Contractors, or MACs, announced that they are withdrawing their final Local Coverage Determinations, or LCDs, for MIGS that were scheduled to take effect on January 29 and calls the fact that there will be no change in January to the current CMS coverage for MIGS procedures performed with OMNI a ” clear positive” for Sight Sciences. However, there is “still work to be done to restart the revenue engine,” adds the firm, which reiterates its Neutral rating and $2.50 price target on Sight Sciences shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SGHT:
- Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
- Sight Sciences announces withdrawal of final LCDs on MIGS from five contractors
- Sight Sciences (NASDAQ:SGHT) Skyrockets 48% after New Glaucoma News
- Sight Sciences to share results of Sahara RCT vs Restasis with Medicare/payers
- Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease